Institut Pascal, Thérapies Guidées par l'Image, CNRS SIGMA UCA UMR 6602 University Hospital Gabriel Montpied Clermont-Ferrand France.
Jacques Lacarin Vichy Hospital Centre Vichy Cedex France.
J Am Heart Assoc. 2024 Nov 5;13(21):e036065. doi: 10.1161/JAHA.124.036065. Epub 2024 Oct 25.
Despite improvement in devices, in-stent restenosis remains a frequent and challenging complication of percutaneous coronary interventions.
The RESTO (Morphological Parameters of In-Stent Restenosis Assessed and Identified by OCT [Optical Coherence Tomography]; study NCT04268875) was a prospective multicenter registry including patients presenting with coronary syndromes related to in-stent restenosis. All patients underwent preintervention OCT analysis, which led to analysis of in-stent restenosis phenotype, number of strut layers, and presence of stent underexpansion. The primary end point was the in-stent restenosis type according to the OCT morphological classification. The 1-year incidence of target vessel failure (a composite of death from cardiac causes, target-vessel myocardial infarction, or ischemia-driven target-vessel revascularization) was assessed. The study included 297 patients. The culprit stent was a drug-eluting stent in 74.2% of cases. OCT analysis revealed the presence of neoatherosclerosis in 57% (52% calcified), neointimal hyperplasia in 43% (58% homogeneous), stent underexpansion (minimal stent area <4.5 mm) in 43%, and multiple stent layers in 30%. The prepercutaneous coronary intervention OCT analysis modified the operator's strategy for management in 30% of cases. Treatment involved drug-eluting stent implantation in 61.6% and drug-eluting balloon angioplasty in 36.1% of cases with only 63.2% optimal results. The 1-year target vessel failure incidence was 11% (95% CI, 9%-13%). Residual postpercutaneous coronary intervention stent underexpansion was associated with significantly higher target vessel failure incidence (19% [95% CI, 14%-24%] versus 7% [95% CI, 5-9], =0.01).
OCT identified neoatherosclerosis and neointimal hyperplasia in comparable proportions. Stent underexpansion was frequent and favored subsequent adverse clinical outcomes.
尽管器械有所改进,但支架内再狭窄仍然是经皮冠状动脉介入治疗的常见且具有挑战性的并发症。
RESTO(通过光学相干断层扫描(OCT)评估和识别的支架内再狭窄的形态学参数;研究 NCT04268875)是一项前瞻性多中心注册研究,纳入了因支架内再狭窄而出现冠状动脉综合征的患者。所有患者均接受了术前 OCT 分析,该分析导致了支架内再狭窄表型、支架层数量和支架扩张不足的分析。主要终点是根据 OCT 形态学分类的支架内再狭窄类型。评估了 1 年时靶血管失败(由心脏原因死亡、靶血管心肌梗死或缺血驱动的靶血管血运重建的复合终点)的发生率。该研究纳入了 297 例患者。在 74.2%的病例中,罪犯支架为药物洗脱支架。OCT 分析显示 57%(52%为钙化)存在新动脉粥样硬化,43%(58%为均匀)存在新生内膜增生,43%存在支架扩张不足(最小支架面积<4.5mm),30%存在多层支架。术前经皮冠状动脉介入治疗 OCT 分析改变了 30%病例的操作者管理策略。治疗方法包括药物洗脱支架植入术(61.6%)和药物洗脱球囊血管成形术(36.1%),仅 63.2%获得了理想的结果。1 年靶血管失败发生率为 11%(95%CI,9%-13%)。经皮冠状动脉介入治疗后残留的支架扩张不足与靶血管失败发生率显著升高相关(19%[95%CI,14%-24%]与 7%[95%CI,5-9],=0.01)。
OCT 以相似的比例识别了新动脉粥样硬化和新生内膜增生。支架扩张不足很常见,并导致随后发生不良临床结局。